Please login to the form below

Not currently logged in
Email:
Password:

osteoporosis

This page shows the latest osteoporosis news and features for those working in and with pharma, biotech and healthcare.

ViiV’s two-drug HIV combo backed by CHMP

ViiV’s two-drug HIV combo backed by CHMP

There was bad news for three other companies, with the CHMP issuing negative opinions for Portola’s Dexxience (betrixaban) for the prevention of venous thromboembolism, Radius International’s osteoporosis candidate Eladynos

Latest news

More from news
Approximately 9 fully matching, plus 200 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Dr Reddy's has expanded its collaboration with Amgen in India adding three approved products: Xgeva for treating bone metastases, Vectibix in colorectal cancer therapy and Prolia for osteoporosis.

  • Medical affairs - the time for change is now Medical affairs - the time for change is now

    FLIP aims at supporting the implementation of Fracture Liaison Services (FLS) for secondary fracture prevention in patients suffering from osteoporosis. ... FLS is a coordinated multidisciplinary approach to patient care. To date the FLIP programme has

  • Pharma deals in June 2015 Pharma deals in June 2015

    The device, which has been tested in the clinic for the delivery of parathyroid hormone in osteoporosis patients, can be programmed to release drug at precise times and on a

  • Pharma deals during December 2014 Pharma deals during December 2014

    34 (PTH) delivered using Zosano's microneedle patch system for the treatment of osteoporosis.

  • Investing in the future of R&D Investing in the future of R&D

    One of UCB's brightest prospects is its osteoporosis candidate romosozumab. In January phase II trial results were published that showed significant increases in low bone mineral density at both spine ... and hip and in June the monoclonal antibody began

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Atlantis Healthcare

    incontinence. • multiple sclerosis. • osteoporosis . • rheumatoid arthritis. Additionally, Atlantis has delivered many programmes to support rare diseases, health screening and blood donor management.

  • Atlantis Healthcare

    incontinence. • multiple sclerosis. • osteoporosis . • rheumatoid arthritis. Additionally, Atlantis has delivered many programmes to support rare diseases, health screening and blood donor management.

  • Maximising ROI from mature brands

    and Evista drug for osteoporosis, underlines the challenges that pharma companies face when patents expire.

  • Patient Compliance – Cracking that Big Nut!

    Non-adherence is a very common problem and a big issue for pharma, especially in chronic disease areas like diabetes, hypertension and osteoporosis.

  • Maximising patient adherence by leveraging the patient/ physician/ pharma relationship

    It’ s a common problem, especially for chronic diseases like diabetes, hypertension and osteoporosis, and one the pharmaceutical industry has invested much time and money trying to solve.

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

MAT offers an information exchange called Rapid Payer Response that allows healthcare stakeholders to secure immediate, global, expert insight and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics